Tabimorelin
NN703 · NNC 26-0703
An orally active ghrelin receptor ligand studied in clinical pharmacology trials as a growth hormone secretagogue. Its development did not lead to approval.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
Not established in a public source. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Not approved for human use; no public label defines handling.
References
- PubChem compound record
- Eur J Clin Pharmacol 2003: clinical pharmacokinetic interaction study of NN703 (tabimorelin)
- Eur J Endocrinol 2004: ghrelin-receptor ligand tabimorelin in leptin-signalling models
Read the source
Related in Growth Hormone
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.